PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework

Diane K Reyes; Shadpour Demehri; Rudolf A Werner; Martin G Pomper; Michael A Gorin; Steven P Rowe; Kenneth J Pienta

doi:10.1016/j.eucr.2019.01.007

PSMA-targeted [¹⁸F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework

Urol Case Rep. 2019 Jan 9:23:72-74. doi: 10.1016/j.eucr.2019.01.007. eCollection 2019 Mar.

Authors

Diane K Reyes¹, Shadpour Demehri², Rudolf A Werner^{2

3}, Martin G Pomper^{1

2}, Michael A Gorin^{1

2}, Steven P Rowe^{1

2}, Kenneth J Pienta¹

Affiliations

¹ The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.

Abstract

We present the case of a man with oligometastatic prostate cancer who underwent a PSMA-targeted 18F-DCFPyL PET/CT scan in order to illustrate how the PSMA-RADS grading sytem can be successfully used to support clinical decision-making and treatment planning. Notably, the presented patient was found to have an equivocal bone lesion (PSMA-RADS-3B) which was further worked up with a tumor protocol MRI and found to be definitively benign (PSMA-RADS-1B) and thus removed from the oligometastatic treatment plan. Remaining avid lesions were incorporated into the treatment plan or deferred for later work-up or monitoring, as indicated within the PSMA-RADS framework.

Keywords: DCFPyL; Oligometastatic; PSMA; Prostate cancer.

Publication types

Case Reports

Abstract

Publication types

Grants and funding